Recently approved by the U.S. Food and Drug Administration for the treatment of Parkinson’s disease psychosis, Nuplazid (pimavanserin) is now available for prescription. The drug, from pharmaceutical company Acadia, is indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.
Learn about Parkinson’s psychosis in our “Ask the MD” blog.
